Skip to content
Screener

Veracyte VCYT Q2 2026 earnings

Reported July 30, 2026 · After market close

Revenue$150.3MBeat by $5.7M
EPS$0.54Beat by $0.13
Revenue estimate$144.6M
EPS estimate$0.41
“These launches meaningfully expand our ability to serve more patients across the cancer care continuum and, combined with the strength of our core business, position us well to deliver durable double-digit growth.”
Marc Stapley

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$147.2M
EPS estimate$0.43

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$3.1B+23.6%
Enterprise value$2.87B+23.0%
P/E35.2×-59.9×
P/S5.7×+0.5×

FAQ

When did Veracyte report Q2 2026 earnings?
Veracyte (VCYT) reported Q2 2026 earnings on July 30, 2026 after market close.
What were Veracyte's Q2 2026 revenue and EPS?
Veracyte reported revenue of $150.3M and eps of $0.54 for Q2 2026.
Did Veracyte beat estimates in Q2 2026?
Revenue beat the consensus estimate of $144.6M by $5.7M. EPS beat the consensus estimate of $0.41 by $0.13.
How did Veracyte's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 15.5% from $130.2M a year earlier and eps grew 22.7% from $0.44.
Where can I find Veracyte's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001384101-26-000042) and the 10-Q periodic report (0001384101-26-000044) directly on SEC EDGAR. The filing index links above go to sec.gov.